All results
60 results for stronger study
-
HBS-101-CL-002
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS)…
- Ages
- 6 Years - 65 Years
- Sexes
- All
-
Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant…
- Ages
- 12 Years - 99 Years
- Sexes
- All
-
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE)
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology…
- Ages
- 18 Years - N/A
- Sexes
- All
-
UCOPE
Osteoarthritis (OA) represents a significant cause of disability worldwide and the knee is the most commonly affected joint. Oxytocin (OT) is a mediator of…
- Ages
- 45 Years - 100 Years
- Sexes
- All
-
Testing the Combination of ZEN-3694 and Talazoparib in Ps w/ Advanced Solid Tumors; ComBET
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Phase I/II Study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patie
Patients with breast cancer are commonly treated with taxane chemotherapy. Some very common side effects of taxanes, such as anemia and peripheral neuropathy,…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
CAPTIVA
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the…
- Ages
- 30 Years - N/A
- Sexes
- All
-
CAPTIVA
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the…
- Ages
- 30 Years - N/A
- Sexes
- All
-
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Fluoxetine in MSK Trauma Patients
Musculoskeletal trauma is one of the leading causes of disability in the United States and its negative quality of life impact extends beyond that of physical…
- Ages
- 18 Years - N/A
- Sexes
- All